Plasma NT-proBNP mirrors the deleterious cardiovascular and renal continuum in hypertension

Courand, P.; Harbaoui, Brahim; Bècle, C.; Moule-Bertin, C.; Lantelme, Pierre

doi:10.1016/s1878-6480(17)30283-5

Cited by 5 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More specifically, patient's with Cushing's syndrome developed a concentric pattern independently of the BP load and dipping status [7,45]. Herein we did not find any correlation of cortisol with different parameters of LVH, but a significant correlation with plasma NT-proBNP, an integrative biomarker of risk in hypertension was observed [14,46]. One hypothesis to explain this point may be the interaction between the adrenal glands and the expression of ventricular mRNA levels of BNP observed in rats models [47].…”

Section: Discussioncontrasting

confidence: 56%

Impact of cortisol on blood pressure and hypertension-mediated organ damage in hypertensive patients

Haddad

Courand

Berge

et al. 2021

Journal of Hypertension

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 56%

Impact of cortisol on blood pressure and hypertension-mediated organ damage in hypertensive patients

Haddad

Courand

Berge

et al. 2021

Journal of Hypertension

View full text Add to dashboard Cite

show abstract

“…24 BNP also has a significant role into the prognosis of target organ damage in patients with hypertension or acute pulmonary embolism. 25 The effects of NT-proBNP on diuresis and natriuresis in congestive HF represent a compensatory mechanism for stress in myocytes, leading to ventricular dysfunction. 26 In addition, NT-proBNP is correlated with the symptoms and echocardiographic severity of mitral stenosis and unstable angina, 27 and is a biomarker of the damage caused by cardiac ischemia or acute coronary syndrome, with prognostic implications.…”

Section: Discussionmentioning

confidence: 99%

Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project

et al. 2020

View full text Add to dashboard Cite

Background The ABC (age, biomarkers, and clinical history)-stroke and ABC-bleeding are biomarker-based scores proposed to predict stroke and bleeding, but non-specificity of biomarkers is common, predicting different clinical events at the same time. We assessed the predictive performance of the ABC-stroke and ABC-bleeding scores, for outcomes beyond ischemic stroke and major bleeding, in a cohort of atrial fibrillation (AF) patients. Methods We included AF patients stable on vitamin K antagonists for 6 months. The ABC-stroke and ABC-bleeding were calculated and the predictive values for myocardial infarction (MI), acute heart failure (HF), a composite of cardiovascular events, and all-cause deaths were compared. Results We included 1,044 patients (49.2% male; median age 76 [71–81] years). During 6.5 (4.3–7.9) years, there were 58 (5.6%) MIs, 98 (9.4%) acute HFs, 167 (16%) cardiovascular events, and 418 (40%) all-cause deaths. There were no differences in mean ABC-stroke and ABC-bleeding scores in patients with/without MI (p = 0.367 and p = 0.286, respectively); both scores were higher in patients with acute HF, cardiovascular events, or death (all p < 0.05). Predictive performances for the ABC-stroke and ABC-bleeding scores were similar, ranging from “poor” for MI (c-indexes ∼0.54), “moderate” for acute HF and cardiovascular events (c-indexes ∼0.60 and ∼0.64, respectively), and “good” for all-cause mortality (c-indexes > 0.70). Clinical usefulness whether assessed by ABC-stroke or ABC-bleeding was similar for various primary endpoints. Conclusion In AF patients, the ABC-stroke and ABC-bleeding scores demonstrated similar predictive ability for outcomes beyond stroke and bleeding, including MI, acute HF, a composite of cardiovascular events, and all-cause deaths. This is consistent with nonspecificity of biomarkers that predict “sick” patients or poor prognosis overall.

show abstract

“…Finally, the performance of natriuretic peptides added to other patient variables for risk stratification deserves consideration also in disease settings other than HF, as suggested by several studies. [17][18][19] The main limitation of this preliminary, hypothesisgenerating study is the presence of two population subgroups. As all variables needed for SHFM calculation were available only for patients with more recent assessment, the SHFM score could be computed only in 39% of patients.…”

Section: Shfm Subgroupmentioning

confidence: 99%

N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure

Arzilli

Aimo

Vergaro

et al. 2018

Eur J Prev Cardiolog

View full text Add to dashboard Cite

Background The Seattle heart failure model or the cardiac and comorbid conditions (3C-HF) scores may help define patient risk in heart failure. Direct comparisons between them or versus N-terminal fraction of pro-B-type natriuretic peptide (NT-proBNP) have never been performed. Methods Data from consecutive patients with stable systolic heart failure and 3C-HF data were examined. A subgroup of patients had the Seattle heart failure model data available. The endpoints were one year all-cause or cardiovascular death. Results The population included 2023 patients, aged 68 ± 12 years, 75% were men. At the one year time-point, 198 deaths were recorded (10%), 124 of them (63%) from cardiovascular causes. While areas under the curve were not significantly different, NT-proBNP displayed better reclassification capability than the 3C-HF score for the prediction of one year all-cause and cardiovascular death. Adding NT-proBNP to the 3C-HF score resulted in a significant improvement in risk prediction. Among patients with Seattle heart failure model data available ( n = 798), the area under the curve values for all-cause and cardiovascular death were similar for the Seattle heart failure model score (0.790 and 0.820), NT-proBNP (0.783 and 0.803), and the 3C-HF score (0.770 and 0.800). The combination of the 3C-HF score and NT-proBNP displayed a similar prognostic performance to the Seattle heart failure model score for both endpoints. Adding NT-proBNP to the Seattle heart failure model score performed better than the Seattle heart failure model alone in terms of reclassification, but not discrimination. Conclusions Among systolic heart failure patients, NT-proBNP levels had better reclassification capability for all-cause and cardiovascular death than the 3C-HF score. The inclusion of NT-proBNP to the 3C-HF and Seattle heart failure model score resulted in significantly better risk stratification.

show abstract

Plasma NT-proBNP mirrors the deleterious cardiovascular and renal continuum in hypertension

Cited by 5 publications

References 0 publications

Impact of cortisol on blood pressure and hypertension-mediated organ damage in hypertensive patients

Impact of cortisol on blood pressure and hypertension-mediated organ damage in hypertensive patients

Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project

N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure

Contact Info

Product

Resources

About